Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™ (IV Plazomicin)

Cipla USA furthers AMR stewardship with acquisition of key 
anti-infective ZEMDRI™ (IV Plazomicin)
 Cipla USA to hold worldwide rights (excluding Greater China) of ZEMDRI™ (IV Plazomicin)
 Plazomicin is an IV aminoglycoside with once-daily dosing for cUTI in adults, with proven 
activity against certain drug-resistant bacteria
 Acquisition consistent with Cipla’s legacy of pioneering contribution to global healthcare 
challenges, industry leadership in anti-microbial resistance (AMR) stewardship practices 
and expertise in manufacturing, marketing and educational programs in the anti-infective
 Product to add depth and synergy to pipeline of specialty products in the U.S.
Warren, New Jersey & Mumbai, India; July 24, 2019: Cipla USA Inc. (“Cipla USA”), a wholly-owned 
subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA 
EQ; hereafter referred to as "Cipla"), announced the acquisition of the prescription drug ZEMDRI™
(Plazomicin) from Achaogen Inc. (“Achaogen”) in a Chapter 11, U.S. Bankruptcy Code auction 
of Achaogen’s assets. Cipla USA has acquired worldwide rights of ZEMDRI™ (excluding Greater 
China) with its allied assets and limited liabilities.
ZEMDRI™ is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated 
urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently 
available treatment options. ZEMDRI™ was approved by the United States Food & Drug 
Administration (USFDA) in June 2018, and was launched in the same year, with patent protection 
expected to continue until 2031 or 2032. It has been granted a new technology add-on payment 
(NTAP) by the Centers for Medicare & Medicaid Services (CMS), for its administration in a hospital 
in-patient setting. The product has also been filed for approval in the European Union (EU).
ZEMDRI™ is the latest milestone in Cipla’s history of proactive and humanitarian leadership in 
enabling access to life-saving drugs. In 2001, at the height of the global HIV movement, Cipla
changed the treatment paradigm with its offer of a triple combination anti-retroviral therapy at 
less than a dollar a day in Africa against the prevailing price of around USD 12,000 a year for one 
patient. With anti-microbial resistance (AMR) today being an urgent global healthcare challenge, 
Cipla has been at the forefront of AMR stewardship. Plazomicin is a novel antibiotic effective 
against some of the cUTI-causing gram-negative bacteria that are resistant to beta-lactam 
antibiotics including carbapenems. Clinical studies have shown sustained microbiological 
eradication of the bacteria with Plazomicin. 
Cipla is a signatory to the Industry Declaration on AMR at the World Economic Forum in Davos in 
2016 that laid out a roadmap to combat AMR. An independent analysis released by the Access 
to Medicine Foundation in January 2018 identified Cipla as one of the drug-makers leading the 
effort to curb overuse of antibiotics, and implement production and source systems that help 
prevent environmental release of antibiotics1. Its Antibiotic Benchmark Report recognised Cipla 
for its work in educating healthcare practitioners (HCPs), illustrating AMR trends in marketing 
material, adapting packaging to support rational use, and engaging in AMR surveillance2. In India, 
Cipla has a long history of antibiotic development from ampicillin in the 1970s to quinolones in the 
1990s. More recently, Cipla introduced the extremely effective antibiotic colistin in India.
Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said: “The acquisition 
of ZEMDRI™ deepens our pipeline of specialty products in the U.S. in our identified focus areas of 
central nervous system, lung delivery of medicines, and institutionally administered products. With 
a robust front-end commercial infrastructure for U.S. hospital sales in place, we expect to extract 
strong synergy from our IV Plazomicin and IV Tramadol assets. Cipla has been a leading industry 
voice in the fight against AMR and our expertise in manufacturing, marketing and conducting 
educational programs in the antibiotic segment makes us well-placed to take ZEMDRI™ globally 
to expand our leadership position.”
About ZEMDRI™:
ZEMDRI™ is an aminoglycoside with once-daily intravenous dosing that has activity against certain 
Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE) and extendedspectrum beta-lactamases (ESBL) producing Enterobacteriaceae. Achaogen's EPIC (Evaluating 
Plazomicin In cUTI) clinical trial successfully evaluated the safety and efficacy of ZEMDRI in adult 
patients with cUTI, including pyelonephritis. ZEMDRI™ is engineered to overcome aminoglycosidemodifying enzymes, the most common aminoglycoside-resistance mechanism in 
Enterobacteriaceae, and has in vitro activity against ESBL- producing, aminoglycoside-resistant, 
and carbapenem-resistant isolates. The Centers for Disease Control and Prevention (CDC) has 
characterized ESBL- producing Enterobacteriaceae as a "serious threat" and CRE as "nightmare 
1 For more: (last accessed July 21, 2019)
2 For more: (last accessed July 21, 2019)
bacteria", which is an immediate public health threat that requires urgent and aggressive action.
The safety profile of Plazomicin is consistent with that of the traditional aminoglycosides. For more 
information on the product, indication and safety including boxed warning, please visit
About Cipla USA:
Cipla USA is a wholly-owned subsidiary of Cipla representing its direct market presence in the U.S., 
and focused on marketing the highest quality pharmaceutical products in the retail and 
institutional spaces in the country. The addition of InvaGen Pharmaceuticals, Inc. and Exelan 
Pharmaceuticals, Inc in 2016, including the manufacturing facilities in New York, strengthened 
Cipla USA’s presence in the U.S. By leveraging Cipla’s strong R&D and manufacturing capabilities, 
Cipla USA has been able to build a strong organic pipeline of limited competition complex 
generic products, and explore an inorganic portfolio of specialty products, all with a view to 
offering meaningful healthcare solutions to patients in the country. Cipla USA is headquartered in 
Warren, New Jersey, and is today among the most dispensed generic players by prescription. For 
more information, please visit
About Cipla: 
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable 
growth, complex generics, and deepening portfolio in our home markets of India, South Africa, 
North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well known. Our 46
manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using 
cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in 
pharma in India (IQVIA MAT Mar’19), 3rd largest in the pharma private market in South Africa 
(IQVIA MAT Mar’19), and is among the most dispensed generic players in the U.S. For over eight 
decades, making a difference to patients has inspired every aspect of Cipla’s work. Our 
paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day 
in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, 
accessibility and affordability to the centre of the movement. A responsible corporate citizen, 
Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and 
deep-rooted community links wherever it is present make it a partner of choice to global health 
bodies, peers and all stakeholders. For more, please visit, or click on 
Twitter, Facebook, LinkedIn.
For queries, please contact: 
Corporate Communications Investor Relations 
Heena Kanal Naveen Bansal 
E-Mail: E-Mail: 
Disclaimer: Except for the historical information contained herein, statements in this document 
may constitute "forward looking statements". These forward-looking statements involve a number 
of risks, uncertainties and other factors that could cause actual results to differ materially from 
those suggested by the forward-looking statements. These risks and uncertainties include, but are 
not limited to, our ability to successfully implement our strategy, our growth and expansion plans, 
our ability to obtain regulatory approvals, technological changes, cash flow projections, our 
exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to 
update forward-looking statements to reflect events or circumstances after the date thereof.